Cooley M&A

JANUARY 22, 2025

Looking ahead, expect the fruits of these efforts to free up valuable resources capital and management bandwidth that can be redirected toward higher-value, strategic acquisitions in 2025 as the general economic backdrop (inflation, interest rates, antitrust) looks to become more conducive to bigger bets.

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64

The Deal

OCTOBER 17, 2023

But some subsectors, such as beauty, fragrance, residential services and medical spas, remained active as risk-off investors shifted deal activity toward categories they view as less discretionary, according to Leonhardt. Public markets, however, have been tepid, with the much-awaited IPO of L Catterton Management Ltd.

M&A 64

M&A IPO Retail Medical 64

Peak Frameworks

SEPTEMBER 19, 2023

For example, in the 2012 Facebook IPO, common shareholders gained exposure to the tech giant's fortunes, while also securing a say in corporate matters. Proponents argue that by fulfilling this responsibility, firms indirectly benefit society by driving economic growth and innovation.

Corporation 52

Corporation Private Equity Mergers and Acquisitions Corporate Finance 52

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 20, 2022

In November, Johnson & Johnson announced that it will split itself into two publicly traded companies , separating its pharmaceutical and medical devices businesses from its consumer products business. There is a history of drugs failing for one use and then being successfully developed for other uses. time highs in 2021.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Focus Investment Banking

FEBRUARY 11, 2025

Traditional terminal exit routes for private equity-backed companies are to larger strategic acquirers (often public companies) and IPOs, where a private company becomes publicly traded. McKesson is primarily a distributor, meaning that it sells pharmaceuticals, medical supplies, and other medical devices and services to healthcare providers.

Private Equity 52

Private Equity Healthcare Equities Medical 52